Episodes
Friday Sep 22, 2017
Friday Sep 22, 2017
According to the 2016 CHEST VTE Guidelines, at least 3 months of therapy is recommended for an unprovoked DVT or PE (Grade 1B). Thereafter, the clinician is expected to weigh the risks and benefits to determine if extended therapy is appropriate. Balancing the risk of mortality from recurrent VTE versus major bleeding has been challenging. A validated clinical decision tool is sorely needed! Until recently, no risk assessment tool has been validated and therefore none have been widely adopted in practice.
Guest Author: Carol Chan, Pharm.D.
Music by Good Talk
Friday Sep 08, 2017
Testing the Limits on Blood Glucose Monitoring: Can We Safely Cut Back?
Friday Sep 08, 2017
Friday Sep 08, 2017
Is self-monitoring of blood glucose (SMBG) cost-effective? SMBG is often recommended to help guide treatment decisions. Consumer-oriented advertising often promotes frequent SMBG as means to achieve better glycemic control but current clinical practice guidelines do not provide specific recommendations regarding the frequency of blood glucose monitoring. The lack of conclusive evidence supporting the clinical benefits of routine SMBG combined with the rising costs of healthcare has led some payers to place limits on SMBG testing supplies. Is this wise policy? Or does it lead to poor health outcomes?
Guest Authors: KyAnn Wisse, PharmD, BCACP and Dawn Fuke, Pharm.D, BCPS
Music by Good Talk